Loading
Lung cancer oncologist who showed plasma genotyping matches tissue and leads Canadian lung trials.
Natasha B. Leighl is Lung Site Lead in Medical Oncology and holds the OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development at the Princess Margaret Cancer Centre. She is a lung cancer oncologist known for leading the NILE study, which showed that plasma cell-free DNA genotyping matches tissue testing in non-small-cell lung cancer, and for leading numerous Canadian Cancer Trials Group lung studies. Her selected paper reports the clinical utility of comprehensive cell-free DNA analysis in newly diagnosed metastatic lung cancer. A past president of the IASLC, she continues to work on liquid biopsy and health economics.
| Title | Journal | Year |
|---|---|---|
| Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer | Clinical Cancer Research | 2019 |